便秘患者的肠道菌群在乳糖干预之前与干预后
Jianxia Ma1, Houlian Ma1, Songbai Zheng1
1Department of Gastroenterology, Hua Dong Hospital, Fu Dan University, Shanghai, PR China.
Medicine
|August 11, 2023
概括
在慢性功能性便秘患者中,乳糖干预增加了有益的肠道细菌. 这优化了肠道环境,有效地缓解了便秘症状.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 人类健康 人类健康 人类健康
背景情况:
- 慢性功能性便秘 (CFC) 是一种普遍存在的胃肠道疾病.
- 肠道微生物组成的变化与CFC有关.
- 乳糖是一种常用于便秘管理的透性松剂.
研究的目的:
- 研究乳糖对CFC患者肠道菌群特征的影响.
- 为了比较CFC患者的肠道微生物群概况与乳糖治疗前后的健康对照.
主要方法:
- 一组29名患有CFC的患者接受15毫升/天口服乳糖一个月.
- 从治疗前和治疗后的患者和20个健康对照组中收集了便样本.
- 用16S rRNA基因测序和生物信息学分析分析了肠道微生物群的组成.
主要成果:
- 在CFC患者中,乳糖治疗显著增加了关键有益细菌的丰富性,包括Bifidobacteria,Bacillus cereus,Prevotella,Bacillus,Anaerostipes,Oribacterium和Mogibacterium.
- 这些细菌群体的数量增加到与健康对照群体相比或超过的水平.
- 在乳糖后的健康对照组中观察到Anaerotruncus的下降,这表明存在差异效应.
结论:
- 乳糖有效调节慢性功能性便秘患者的肠道微生物群.
- 这种干预措施促进了有益益生菌的增加,并优化了肠道微环境.
- 乳糖通过恢复肠道微生物平衡,显示出作为缓解便秘的治疗剂的潜力.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
210
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
210
Bacterial Flora of the Large Intestine
516
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
516
Drugs Affecting GI Tract Motility: Other Laxatives
275
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
275
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
251
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
251
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213
Irritable Bowel Syndrome III: Medical and Nursing Management
240
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
240


